The Global Patent Exchange

Web: www.tynax.com |  Phone: (650)292-4849 |  Email: contact@tynax.com

Patent for Sale:

A Breast Patch To Inhibit Prolactin    

Lactation suppression - aids the relief of discomfort from breast engorgement pain, by drying breast milk after pregnancy.

Overview

This is a holistic breast patch, it is the first known all natural, Federal Drug Administration (FDA) approved non-pharmaceutical device. The breast patch inhibits prolactin production, and safely aids the relief of discomfort from breast engorgement pain. When used as directed the breast patch will successfully eliminate breast engorgement pain within 24-hours, and suppresses postpartum milk production within three to ten days; by comparison to six to eight weeks or longer without use.

Primary Application of the Technology

The target audience are postpartum women who elects not to breastfeed and women who want to discontinue breastfeeding.

The Problem Solved by the Technology

The breast patch was invented for the purpose of aiding in the suppression of breast milk and relieving breast engorgement pain, women experience after childbirth. When used as directed the transdermal patch will successfully eliminate breast engorgement pain within 24-hours, and suppresses postpartum milk production within three to ten days; by comparison to six to eight weeks or longer without use.

How the Technology Solves the Problem

After pregnancy, a woman naturally produces breast milk for a period of time. Women who choose not to breast-feed experience discomfort and pain due to breast engorgement. Relief is sought through breast pumping stimulation, which prolongs production and delays suppression of milk production; ice packs, and breast binding, which can cause mastitis; and various other means that have proven to be dangerous or otherwise unsuccessful.

Competitive Advantage

Currently, there are no approved Federal Drug Administration (FDA), treatment for lactation suppressant and breast engorgement pain relief (over-the-counter or prescription). A variety of issues and concerns may prevent a mother from breastfeeding, some of these challenges includes, but not limited to:

Stillbirth
Adoption
Health reasons
Prescription medications
Employment/frequent travel
Complications from surgery
Immature birth

Comments on Deal Structure, Potential Terms and Restrictions

The objective is to sell the U.S. patent rights on "assignment" to a pharmaceutical company and/or investor with an interest in intellectual property (IP).

Frequently Asked Questions

Q. How does the breast patch work?

The scientific method is called “Transdermal Infusion System” ( applied to the skin). The breast patch is approximately 1 ½ inch by ¾ inch in size and applied to the chest region of a postpartum woman.

Q. Is the breast patch all natural?

The device is comprised of a unique, organic carbonyl disc housed within a cotton gauze and nonstick adhesive, the interior disc of the patch consists of all natural fibers. Therefore, no warnings or precautions are required when marketed.

Additional Information

The current stage of development is pre-clinical trial, to determine safety and effectiveness. The breast patch will have a significant impact for all postpartum women.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 604: Surgery


View this listing on the Tynax website: www.tynax.com/listing/6161